Filing Details

Accession Number:
0001209191-19-013905
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-02-26 21:42:59
Reporting Period:
2019-02-22
Accepted Time:
2019-02-26 21:42:59
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1636651 Ovid Therapeutics Inc. OVID () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1256153 M Jeremy Levin C/o Ovid Therapeutics Inc.
1460 Broadway, Suite 15044
New York NY 10036
Ceo Yes Yes Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-02-22 75,000 $2.00 4,676,529 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Acquisiton 2019-02-24 250,000 $0.00 250,000 $1.89
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
250,000 2029-02-23 No 4 A Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 35,461 Indirect See Footnote
Common Stock 465,116 Indirect See Footnote
Footnotes
  1. The reportable securities are owned directly by Divo Holdings, LLC ("Divo"). The Reporting Person's spouse in the manager of Divo. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose.
  2. The reportable securities are owned directly by DSL-EAL Holdings LLC (the "LLC"). The Reporting Person is the manager of the LLC. The Reporting Person may be deemed to share voting and investment powers for the shares held by the LLC. The Reporting Person disclaims beneficial ownership of the shares held by the LLC and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose, except to the extent of any pecuniary interest therein.
  3. 25% of the shares subject to the Stock Option will vest and become exercisable on February 24, 2020 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date.